Goal of Dynamic Strategy by Aggressive Lipid Intervention in Acute Myocardial Infarction

Goal of Dynamic Strategy by Aggressive Lipid Intervention in Acute Myocardial Infarction - GOODBYLIPID-AMI

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056844

Enrollment

300

Registered

2025-02-02

Start date

2025-02-02

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following eligibility criteria (1) 18 years of age or older and less than 85 years of age (2) Have one of the following residual lesions at the time of PCI for AMI i) Coronary angiographic stenosis between 25% and 75%. ii) Coronary angiographic stenosis of 75% to less than 90% and FFR >0.80 or Resting Index >0.89 (3) Fasting LDL-C level >55 mg/dL during hospitalization (4) Written consent for participation in the study is obtained from the patient.

Exclusion criteria

Exclusion criteria: (1) eGFR<30 ml/min/1.73m2 (2) Current or historical use of PCSK9 inhibitors or sustained LDL-C-lowering siRNA agents (3) Scheduled PCI or CABG for residual coronary artery lesions under study (4) Complicated congenital heart disease (5) Patients with a permanent pacemaker or internal defibrillation leads (6) Patients after artificial heart valve replacement (7) Patients with arrhythmia or tachycardia that interferes with CT data acquisition (8) Patients with body mass index (BMI) >35 (9) Patients with contraindication to nitrates (10) Patients with no prognosis for more than 1-year (11) Patients who participated in clinical trials with other drugs (11) Patients participating in clinical trials with other drugs (12) Patients under conditions that may interfere with patient safety or protocol compliance (13) Patients who are deemed unsuitable by the principal investigator or sub investigator

Design outcomes

Primary

Measure	Time frame
Since this is an exploratory study to determine the efficacy of lipid-lowering therapy for residual coronary plaque in non-culprit lesions in patients undergoing PCI for AMI, the principal investigator or investigators will determine the endpoints and analysis methods after data collection.	—

Countries

Japan

Contacts

Public ContactKazutaka Nogi

Nara Medical University Department of Cardiovascular Medicine

nogi18kazu@dream.jp0744-22-3051

Outcome results